

# Riding high on strong JLR performance

## Strong JLR performance should continue on Evoque sales and robust growth in China

February 29, 2012

<b>Rating</b> Remains	<b>Buy</b>
<b>Target price</b> Increased from 200	INR 326
<b>Closing price</b> February 28, 2012	INR 273
<b>Potential upside</b>	+19.4%

### Action: Maintain Buy with a revised TP of INR326; offers 19% upside

TTMT reported strong 3QFY12 results (23-35% ahead of our and consensus expectations) driven by a strong JLR performance. We expect JLR's margins (IFRS) to remain around 18% given currency tailwinds, increasing China contribution and operating leverage benefits due to robust volume growth. Despite strong outperformance over the past six months, valuations are reasonable, in our view. Maintain Buy.

### Catalysts: Strong Evoque volumes, China mix and re-rating of JLR

- Strong Evoque volumes: Evoque has been very successful with JLR selling ~9,000 units/month. The order book for Evoque is full for the next two-three months which should lead to strong volume growth for JLR.
- Robust growth in China: JLR volumes in China increased by 81% y-y in 3QFY12 and accounted for 17% of total JLR sales. We expect the contribution of China to increase to 20% in the next few months, which augurs well for JLR's profitability.
- Further re-rating of the JLR business: If JLR continues to report strong volume growth and margins, we believe there is a possibility that the EV/EBITDA multiple could further re-rate from the current levels.

### Valuation: SOTP-based TP increased to INR326

We raise our valuation for the JLR business to INR219.3 (earlier INR73.1) based on 3.0x FY14F EV/EBITDA (earlier 2.5x) as we factor in stronger-than-expected volume growth and margins. We cut our valuation for the standalone business to INR80.0 (8x FY14F EV/EBITDA) from INR 94.1 on weaker-than-expected margins for FY13F (7.5% vs. 9.3% earlier). We value other investments at INR26.8 (INR31.8 earlier). Note that we roll forward our TP to FY14F from FY13F earlier.

31 Mar	FY11	FY12F		FY13F		FY14F	
Currency (INR)	Actual	Old	New	Old	New	Old	New
<b>Revenue (mn)</b>	1,231,333	1,475,582	1,622,788	1,651,867	1,891,914	1,792,711	2,066,115
<b>Reported net profit (mn)</b>	92,736	87,395	109,314	93,594	139,846	101,978	151,582
<b>Normalised net profit (mn)</b>	90,998	87,395	109,314	93,594	139,846	101,978	151,582
<b>Normalised EPS</b>	28.54	27.41	34.28	29.35	43.86	31.98	47.54
<b>Norm. EPS growth (%)</b>	433.3	-4.0	20.1	7.1	27.9	9.0	8.4
<b>Norm. P/E (x)</b>	9.6	N/A	8.0	N/A	6.2	N/A	5.7
<b>EV/EBITDA (x)</b>	5.6	3.9	4.8	3.4	3.6	3.0	3.1
<b>Price/book (x)</b>	4.5	N/A	3.1	N/A	2.2	N/A	1.7
<b>Dividend yield (%)</b>	1.5	N/A	1.7	N/A	1.9	N/A	2.2
<b>ROE (%)</b>	67.7	38.5	45.9	31.3	40.6	27.4	32.5
<b>Net debt/equity (%)</b>	113.9	88.8	99.8	61.9	62.6	46.6	38.0

Source: Company data, Nomura estimates

**Key company data:** See page 2 for company data and detailed price/index chart.

### Anchor themes

Volume growth expectations for the JLR business remain robust on China and sales of the newly launched Evoque. Currency tailwinds and higher China contribution augur well for JLR margins.

### Nomura vs consensus

Our FY13F consolidated EPS estimates are ~17% above consensus. Consensus is building ~17% margins for JLR compared to our estimate of 18%.

### Research analysts

#### India Autos & Auto Parts

**Kapil Singh - NFASL**  
[kapil.singh@nomura.com](mailto:kapil.singh@nomura.com)  
 +91 22 4037 4199

**Nishit Jalan - NSFSP**  
[nishit.jalan@nomura.com](mailto:nishit.jalan@nomura.com)  
 +91 22 4037 4362

See Appendix A-1 for analyst certification, important disclosures and the status of non-US analysts.

# Key data on Tata Motors

## Income statement (INRmn)

Year-end 31 Mar	FY10	FY11	FY12F	FY13F	FY14F
<b>Revenue</b>	<b>925,193</b>	<b>1,231,333</b>	<b>1,622,788</b>	<b>1,891,914</b>	<b>2,066,115</b>
Cost of goods sold	-654,695	-838,029	-1,136,180	-1,322,309	-1,448,756
<b>Gross profit</b>	<b>270,498</b>	<b>393,304</b>	<b>486,608</b>	<b>569,604</b>	<b>617,359</b>
SG&A	-140,692	-178,257	-217,260	-239,360	-257,517
Employee share expense	-87,518	-93,427	-115,324	-128,291	-141,027
<b>Operating profit</b>	<b>42,288</b>	<b>121,620</b>	<b>154,025</b>	<b>201,953</b>	<b>218,815</b>
<b>EBITDA</b>	<b>81,160</b>	<b>168,175</b>	<b>210,274</b>	<b>274,408</b>	<b>301,596</b>
Depreciation	-38,871	-46,555	-56,250	-72,455	-82,781
Amortisation					
EBIT	42,288	121,620	154,025	201,953	218,815
Net interest expense	-22,397	-20,454	-19,922	-20,774	-17,766
Associates & JCEs	845	1,014	1,064	1,117	1,173
Other income	416	723	1,118	1,168	1,221
<b>Earnings before tax</b>	<b>21,152</b>	<b>102,902</b>	<b>136,285</b>	<b>183,464</b>	<b>203,444</b>
Income tax	-5,582	-11,419	-26,713	-43,324	-51,522
<b>Net profit after tax</b>	<b>15,570</b>	<b>91,483</b>	<b>109,572</b>	<b>140,140</b>	<b>151,922</b>
Minority interests	-303	-485	-258	-294	-340
Other items					
Preferred dividends					
<b>Normalised NPAT</b>	<b>15,267</b>	<b>90,998</b>	<b>109,314</b>	<b>139,846</b>	<b>151,582</b>
Extraordinary items	10,444	1,739	0	0	0
<b>Reported NPAT</b>	<b>25,711</b>	<b>92,736</b>	<b>109,314</b>	<b>139,846</b>	<b>151,582</b>
Dividends	-8,591	-12,742	-14,519	-16,697	-19,201
<b>Transfer to reserves</b>	<b>17,120</b>	<b>79,994</b>	<b>94,795</b>	<b>123,149</b>	<b>132,381</b>

## Valuation and ratio analysis

FD normalised P/E (x)	51.1	9.6	8.0	6.2	5.7
FD normalised P/E at price target (x)	60.9	11.4	9.5	7.4	6.9
Reported P/E (x)	30.3	9.4	8.0	6.2	5.7
Dividend yield (%)	1.1	1.5	1.7	1.9	2.2
Price/cashflow (x)	7.2	7.5	6.1	4.4	3.8
Price/book (x)	9.5	4.5	3.1	2.2	1.7
EV/EBITDA (x)	12.2	5.6	4.8	3.6	3.1
EV/EBIT (x)	23.2	7.8	6.6	4.9	4.3
Gross margin (%)	29.2	31.9	30.0	30.1	29.9
EBITDA margin (%)	8.8	13.7	13.0	14.5	14.6
EBIT margin (%)	4.6	9.9	9.5	10.7	10.6
Net margin (%)	2.8	7.5	6.7	7.4	7.3
Effective tax rate (%)	26.4	11.1	19.6	23.6	25.3
Dividend payout (%)	33.4	13.7	13.3	11.9	12.7
Capex to sales (%)	7.2	7.8	11.8	7.9	7.2
Capex to depreciation (x)	1.7	2.1	3.4	2.1	1.8
ROE (%)	18.9	67.7	45.9	40.6	32.5
ROA (pretax %)	10.2	14.6	14.7	15.8	15.4

## Growth (%)


Revenue	39.7	33.1	31.8	16.6	9.2
EBITDA	166.9	107.2	25.0	30.5	9.9
EBIT	370.9	187.6	26.6	31.1	8.3
Normalised EPS	474.7	433.3	20.1	27.9	8.4
Normalised FDEPS	595.4	433.3	20.1	27.9	8.4

## Per share

Reported EPS (INR)	9.01	29.08	34.28	43.86	47.54
Norm EPS (INR)	5.35	28.54	34.28	43.86	47.54
Fully diluted norm EPS (INR)	5.35	28.54	34.28	43.86	47.54
Book value per share (INR)	28.76	60.13	89.12	126.89	165.61
DPS (INR)	3.01	4.00	4.55	5.24	6.02

Source: Company data, Nomura estimates

## Relative performance chart (one year)



Source: ThomsonReuters, Nomura research

(%)	1M	3M	12M
Absolute (INR)	14.0	50.3	26.2
Absolute (USD)	14.6	59.1	16.5
Relative to index	12.4	41.7	28.8
Market cap (USDmn)	14,995.1		
Estimated free float (%)	60.0		
52-week range (INR)	292.7/137.55		
3-mth avg daily turnover (USDmn)	77.18		
Major shareholders (%)			
Tata Sons	25.9		
LIC	8.5		

Source: Thomson Reuters, Nomura research

## Notes

Strong JLR margins should lead to higher consolidated EBITDA margins

**Cashflow (INRmn)**

Year-end 31 Mar	FY10	FY11	FY12F	FY13F	FY14F
EBITDA	81,160	168,175	210,274	274,408	301,596
Change in working capital	44,630	-11,217	-22,596	-13,151	-4,205
Other operating cashflow	-18,069	-40,978	-44,710	-62,107	-67,233
<b>Cashflow from operations</b>	<b>107,720</b>	<b>115,980</b>	<b>142,968</b>	<b>199,150</b>	<b>230,158</b>
Capital expenditure	-66,601	-96,423	-191,621	-149,700	-149,700
<b>Free cashflow</b>	<b>41,119</b>	<b>19,557</b>	<b>-48,653</b>	<b>49,450</b>	<b>80,458</b>
Reduction in investments	-9,617	-3,251	0	0	0
Net acquisitions					
Reduction in other LT assets	6,365	0	0	0	0
Addition in other LT liabilities	6,646	1,190	0	0	0
Adjustments	-1,776	-4,721	0	0	0
<b>Cashflow after investing acts</b>	<b>42,736</b>	<b>12,775</b>	<b>-48,653</b>	<b>49,450</b>	<b>80,458</b>
Cash dividends	-9,919	-14,670	-16,871	-19,401	-22,312
Equity issue	14,048	47,032	0	0	-5,819
Debt issue	1,345	-23,170	122,065	-5,627	-33,579
Convertible debt issue	0	0	0	0	0
Others	-1,895	331	258	294	340
<b>Cashflow from financial acts</b>	<b>3,579</b>	<b>9,523</b>	<b>105,451</b>	<b>-24,735</b>	<b>-61,370</b>
<b>Net cashflow</b>	<b>46,314</b>	<b>22,298</b>	<b>56,799</b>	<b>24,715</b>	<b>19,088</b>
Beginning cash	41,213	87,433	109,479	166,278	190,993
Ending cash	87,528	109,731	166,278	190,993	210,081
Ending net debt	263,650	218,435	283,701	253,358	200,691

Source: Company data, Nomura estimates

**Notes**

We expect strong cashflows over FY12-14F

**Balance sheet (INRmn)**

As at 31 Mar	FY10	FY11	FY12F	FY13F	FY14F
Cash & equivalents	87,433	109,479	166,278	190,993	210,081
Marketable securities	0	0	0	0	0
Accounts receivable	71,912	68,774	92,974	106,462	116,262
Inventories	113,120	140,705	194,827	221,092	241,162
Other current assets	151,991	191,391	287,423	327,733	358,748
<b>Total current assets</b>	<b>424,456</b>	<b>510,349</b>	<b>741,502</b>	<b>846,280</b>	<b>926,254</b>
LT investments	22,191	25,443	25,443	25,443	25,443
Fixed assets	385,063	434,931	570,302	647,547	714,466
Goodwill	34,229	35,848	35,848	35,848	35,848
Other intangible assets	0	0	0	0	0
Other LT assets	0	0	0	0	0
<b>Total assets</b>	<b>865,940</b>	<b>1,006,571</b>	<b>1,373,094</b>	<b>1,555,117</b>	<b>1,702,010</b>
Short-term debt	0	0	0	0	0
Accounts payable	219,823	266,848	376,612	420,936	458,595
Other current liabilities	197,385	202,990	244,984	267,572	286,594
<b>Total current liabilities</b>	<b>417,208</b>	<b>469,838</b>	<b>621,596</b>	<b>688,508</b>	<b>745,189</b>
Long-term debt	351,084	327,914	449,979	444,351	410,772
Convertible debt	0	0	0	0	0
Other LT liabilities	13,448	14,638	14,638	14,638	14,638
<b>Total liabilities</b>	<b>781,740</b>	<b>812,390</b>	<b>1,086,213</b>	<b>1,147,497</b>	<b>1,170,599</b>
Minority interest	2,135	2,466	2,724	3,018	3,358
Preferred stock	0	0	0	0	0
Common stock	5,706	6,377	6,377	6,377	6,377
Retained earnings	76,359	185,338	277,781	398,225	521,676
Proposed dividends					
Other equity and reserves					
<b>Total shareholders' equity</b>	<b>82,065</b>	<b>191,715</b>	<b>284,158</b>	<b>404,602</b>	<b>528,053</b>
<b>Total equity &amp; liabilities</b>	<b>865,940</b>	<b>1,006,571</b>	<b>1,373,094</b>	<b>1,555,117</b>	<b>1,702,010</b>

**Notes**

We expect net debt/equity to decline gradually over FY12-14F

**Liquidity (x)**

Current ratio	1.02	1.09	1.19	1.23	1.24
Interest cover	1.9	5.9	7.7	9.7	12.3

**Leverage**

Net debt/EBITDA (x)	3.25	1.30	1.35	0.92	0.67
Net debt/equity (%)	321.3	113.9	99.8	62.6	38.0

**Activity (days)**

Days receivable		20.9	18.2	19.2	19.7
Days inventory		55.3	54.0	57.4	58.2
Days payable		106.0	103.6	110.1	110.8
Cash cycle	0.0	-29.9	-31.4	-33.4	-32.9

Source: Company data, Nomura estimates

## Riding high on strong JLR performance

TTMT reported strong 3QFY12 results (23-35% ahead of our and consensus expectations) driven by the robust performance of the JLR business. We expect JLR margins (IFRS) to remain around 18% in FY13F (18.6% in 3QFY12) given currency tailwinds, increasing China contribution and operating leverage benefits. Our volume expectations remain strong on China growth and newly launched Evoque sales. Despite the strong outperformance over the past six months, valuations are reasonable, in our view. Maintain Buy rating.

### JLR – Key growth drivers remain firmly in place

JLR reported 30-45% growth in monthly sales volumes over the past six months driven by the successful launch of Evoque and strong growth in China. Better product mix and higher sales contribution from China resulted in strong margins for the company as well. As per IFRS, JLR's 3QFY12 IFRS EBITDA margins came in at 17%. However, as per the company, EBITDA was lower by GBP60mn due to a one-off forex loss on the evaluation of long-term monetary liabilities. Adjusted for this, margins were 18.6%, which surprised us positively. We were expecting margins of around 15%. We believe that margins could surprise relative to consensus expectations of 17% in FY13F as the demand pull is strong, the strong growth in China continues and currency tailwinds are further favorable at around 1% of margins from 3QFY12 levels. For our FY13-FY14 estimates, we are now building in 18% IFRS margins.

Overall, we believe that the key growth drivers for JLR remain firmly in place. Therefore, we increase our volume estimates for JLR by 11-16% for FY12-14F. We now estimate Evoque sales volume of 57,500 units in FY12F (25,000 earlier) and 85,000 units in FY13F (45,000 earlier). Our new volume estimates are 357,217 units in FY13F. We expect 9% growth in existing models (ex-Evoque) in FY13F to account for the improvement in Freelander volumes, which are currently impacted by production constraints. We expect FY13F EBITDA margins of 18.0% (12.6% earlier). Overall, we increase our EBITDA estimates by around 50% for FY13-14F.

Fig. 1: JLR estimates

	New			Old			% change		
	FY12E	FY13E	FY14E	FY12F	FY13F	FY14F	FY12F	FY13F	FY14F
Volumes (Numbers)	307565	357217	379994	276544	310267	327405	11.2	15.1	16.1
Revenue (GBP m)	13284	15327	16650	11956	13454	14530	11.1	13.9	14.6
Realization/Vehicle (GBP)	43191	42906	43815	43232	43361	44380	(0.1)	(1.0)	(1.3)
YoY (%)	6.2	(0.7)	2.1	6.3	0.3	2.3			
EBITDA* (GBP m)	2,143	2,758	3,013	1,551	1,699	1,844	38.2	62.4	63.4
OPM (%)	16.1%	18.0%	18.1%	13.0%	12.6%	12.7%	3.2	5.4	5.4
PAT (GBP m)	1231.9	1544.5	1654.8	893.0	920.1	977.6	37.9	67.9	69.3

Note: \* As per IFRS

Source: Nomura estimates

### We expect Evoque volume of 85,000 in FY13F

We believe that current monthly Evoque volume of 8,500-9,000 units is partly driven by strong bookings on hand. We expect the monthly run rates to settle down to a lower level of around 7,000 incremental units per month next year. We expect Evoque sales volume of 85,000 units in FY13F and 90,000 units in FY14F. We believe that new launches generally peak around the second or third year of full-year sales. This was true for both BMW X1 launched in 2009 and BMW X3 in 2004. Even volumes of Audi Q5, which started production in 2008, continued to increase in CY11. Audi Q5 sales rose 20% y-y in 9M CY11.

Overall, sales volume of competing models (BMW X1, X3 and Audi Q5) were 100,000 plus each in CY10 and CY11. If Evoque manages to achieve such levels, there could be upside to our estimates.

Fig. 2: A comparison of Evoque with BMW and Audi models

Features	Unit	BMW X1	BMW X3	Evoque	Audi Q3	Audi Q5
Displacement	cc	1995	1995	2200	1995	1995
Power	bhp	143	184	150	140	143
Co2 emissions	g/Km	136	147	133	138	162
Fuel efficiency	Ltr/100Km	5.2	5.6	5.0	5.2	6.2
Torque	N-m	320	380	380		
Top speed	mph	124	130	112		
Base variant price	GBP	24,420	31,440	27,955	24,560	28,000
Top variant price	GBP	31,425	42,225	38,380	31,360	40,765
Volumes						
CY10	000	100	46			109
CY11	000	126	118			131

Note: Audi Q5 volumes are for the first nine months of the year

Source: Company, JD Power estimates, Nomura research

## Steady increase in the luxury car market share for JLR

JLR saw a steady increase in its luxury car market share from 5.5% to 7% over 2QCY10-4QCY11. In particular, the company has done very well in China – increasing its market share by more than 300bps over the same period last year. In our previous note, “Driving on Chinese Affluence” dated 21 Sep, 2011, we discussed how JLR was focusing to increase its market share in China. Increase in dealerships and models tailor made to Chinese customers preferences have helped the company improve market share in China, in our view. We also expect a possible JV announcement with a local player for assembly in China could come soon. This would help JLR cut import duties from 84% to 16% and thus address a much larger segment. We believe such a JV could become operational in FY14F.

Over the past quarter, market share has also been helped by the launch of new model Evoque in 3QCY11 which should continue to ramp up.

Fig. 3: JLR volume comparison with other Luxury OEMs

								YoY		
China volumes	2QCY10	3QCY10	4QCY10	1QCY11	2QCY11	3QCY11	4QCY11	2QCY11	3QCY11	4QCY11
JLR	5,131	5,365	8,196	8,222	9,525	10,880	14,817	86%	103%	81%
<b>Total</b>	<b>141,300</b>	<b>158,620</b>	<b>155,042</b>	<b>174,040</b>	<b>198,225</b>	<b>195,998</b>	<b>216,137</b>	<b>40%</b>	<b>24%</b>	<b>39%</b>
JLR's market share	3.6%	3.4%	5.3%	4.7%	4.8%	5.6%	6.9%			
US volumes	2QCY10	3QCY10	4QCY10	1QCY11	2QCY11	3QCY11	4QCY11	2QCY11	3QCY11	4QCY11
JLR	13,398	13,338	14,359	11,428	13,046	11,728	17,201	-3%	-12%	20%
<b>Total</b>	<b>158,285</b>	<b>164,751</b>	<b>173,294</b>	<b>160,584</b>	<b>176,123</b>	<b>171,715</b>	<b>218,315</b>	<b>11%</b>	<b>4%</b>	<b>26%</b>
JLR's market share	8.5%	8.1%	8.3%	7.1%	7.4%	6.8%	7.9%			
Europe volumes	2QCY10	3QCY10	4QCY10	1QCY11	2QCY11	3QCY11	4QCY11	2QCY11	3QCY11	4QCY11
JLR	29,251	24,608	27,393	31,839	24,716	30,629	34,789	-16%	24%	27%
<b>Total</b>	<b>594,790</b>	<b>519,884</b>	<b>566,752</b>	<b>552,341</b>	<b>634,921</b>	<b>547,157</b>	<b>590,914</b>	<b>7%</b>	<b>5%</b>	<b>4%</b>
JLR's market share	4.9%	4.7%	4.8%	5.8%	3.9%	5.6%	5.9%			
Overall Volumes								YoY		
JLR	59,201	55,134	63,155	66,131	62,090	68,000	86,322	5%	23%	37%
<b>Total</b>	<b>1,074,652</b>	<b>1,013,237</b>	<b>1,063,673</b>	<b>1,072,206</b>	<b>1,210,504</b>	<b>1,124,657</b>	<b>1,228,224</b>	<b>13%</b>	<b>11%</b>	<b>15%</b>
JLR's market share	5.5%	5.4%	5.9%	6.2%	5.1%	6.0%	7.0%			

Note: Market share above is based on the combined volumes of Audi, BMW, Mercedes and JLR

Source: Company data, Nomura estimates

## Several new launches planned in FY14F which could lead to upside risks to our volume estimates

We have not built in additional volumes from the small Jaguar (Jag XE) which is expected to be launched in FY14F. We note that the small Jaguar will likely compete with the existing models like Audi A4, BMW 3 Series and Mercedes C class, which have a combined market volume of around 1.1mn vehicles. The company's current Jaguar XF model, which competes with Audi A6, BMW 5 Series and Mercedes E class (see Fig below), has a market share of around 3.5-4%, according to our calculations. If JLR is able to achieve similar market share in the new smaller Jaguar as well, volumes of Jag XE could be around 40,000 units, on our estimates. This would pose an upside risk to our current volume growth estimates of around 57,000 units (up 5% y-y) for Jaguar in FY14F. Similarly, JLR is coming up with five new models/variants in FY14F (see below); we have not factored in a potential significant increase in volume from these models.

**Fig. 4: New launches for JLR and other competitors**


Text in bold represents launch of a new model; others represent facelift

	FY10	FY11	FY12F	FY13F	FY14F	FY15F
Jaguar XE			<b>BMW 3 F30/31</b> BMW 3 E90 Audi A4 AU481/2 <b>Merc C- Coupe 1</b> Acura TL 2FC <b>Lexus ES 041L</b> <b>Lexus IS 030L</b>	<b>BMW 3 - GT 1</b> Audi A4L AU481	<b>Jaguar XE 1</b> <b>Merc C W205</b> <b>Acura TL 2FC</b> <b>Hyundai Genesis BH</b>	<b>Audi A4 AU491/2</b> Lexus IS 030L
Jaguar XF		<b>Audi A6 AU571/2/6</b>	<b>Jaguar XF X250</b> <b>Audi A6L C6</b>	<b>Infiniti G L53A</b>	BMW 5 - GT F07 Merc E- Coupe C207 Merc E- W212	<b>Jaguar Sub-XF X760</b> <b>Jaguar XF X251</b> Audi A6 AU571/2/6 Audi A6L C6
Jaguar XJ	<b>Jaguar XJ</b>			BMW 7 - F01/F02 <b>Merc S- Coupe C216</b>	<b>Jaguar XJ X351</b> Audi A8 AU641 <b>Merc S- W222</b>	<b>BMW 7 - F01/F02</b>
Jaguar XK			<b>Merc SL- R231</b> <b>Porsche 911 998</b>	BMW 7 - F01/F02	<b>Jaguar XK8 X151</b> Audi A8 AU641	<b>BMW 7 - F01/F02</b>
Defender		<b>Audi Q3 AU316</b>	<b>Merc B- W246</b>		BMW X1 E84 Audi Q3 AU316 <b>Merc B- X156</b>	<b>Defender L317</b> Merc B- W246
Discovery	<b>Volvo XC90 P28</b>	<b>BMW X3 F25</b>	<b>Merc M- W166</b>		<b>Audi Q7 AU736</b>	BMW X3 F25 Merc M- W166 Volvo XC90 P28
Freelander 2		<b>Audi Q3 AU316</b>	<b>Merc B- W246</b>		<b>Freelander L359</b> BMW X1 E84 Audi Q3 AU316 <b>Merc B- X156</b>	Merc B- W246
Range Rover				<b>Range Rover L405</b> <b>Merc GL- X166</b>		
Range Rover Sport		<b>Porsche Cayenne PO726</b>		Lexus RX 642L	<b>Range Rover Sport L494</b> <b>BMW X5 F15</b> <b>BMW X6 F16</b> Porsche Cayenne PO726	<b>Lexus RX 642L</b> <b>Cadillac SRX T2YL</b>
Evoque		<b>BMW X3 F25</b>	<b>Evoque</b>	Audi Q5 AU416 <b>Acura MDX 2PF</b> Land Cruiser 404T	Land Cruiser Prado 6111	BMW X3 F25 <b>Volvo XC60 Y413</b>

Source: JD Power, Nomura research

**Fig. 5: Models in the luxury SUV and car space**

X axis indicates the prices in GBP; figures in ( ) are annual production volume (in '000) in 2010



Source: JD Power, Nomura research

**Factoring in 27% JLR volume growth in China in FY13F**

We are building in 27% volume growth in China in FY13F. We factor in 20% growth in volume of older models (ex-Evoque) in China in FY13F. Also, we estimate 20% of Evoque sales to come from China.

Even though the growth rates would moderate from the 100% y-y growth seen so far in FY12 to 27% in FY13F, we expect volume contribution from China to increase to 20% in

FY13F (17% in 3QFY12). China being a much higher ASP market for the company, a higher sales mix would augur well for JLR's margins as well, in our view.

We note that despite a 27% decline in the passenger vehicles sales in China in Jan-12, the sales of luxury cars remained strong. The total luxury sales of Audi, BMW and Mercedes increased by 19% y-y in Jan-12. JLR's wholesale sales in China increased by around 50% y-y in Jan-12, according to the company.

**Fig. 6: JLR volume estimates**

	Sales volume			YoY (%)		
	FY12F	FY13F	FY14F	FY12F	FY13F	FY14F
North America	50,317	53,704	55,315	(4.2)	6.7	3.0
UK	49,934	52,145	53,710	(14.7)	4.4	3.0
Europe	44,495	47,254	48,672	(18.4)	6.2	3.0
Russia	14,331	15,112	15,566	22.2	5.4	3.0
China	45,152	54,498	62,278	67.8	20.7	14.3
Other	45,837	49,504	54,454	16.4	8.0	10.0
<b>Total (Excl Evoque)</b>	<b>250,065</b>	<b>272,217</b>	<b>289,994</b>	<b>2.6</b>	<b>8.9</b>	<b>6.5</b>
Evoque sales	57,500	85,000	90,000			
Total - Overall sales	307,565	357,217	379,994	<b>26.2</b>	<b>16.1</b>	<b>6.4</b>
<b>Volume mix (%)</b>						
North America	20.1	19.7	19.1			
UK	20.0	19.2	18.5			
Europe	17.8	17.4	16.8			
Russia	5.7	5.6	5.4			
China	18.1	20.0	21.5			
Other	18.3	18.2	18.8			

Source: Nomura estimates

**Fig. 7: Y-Y growth of other luxury OEMs in China**

	Audi	BMW	Mercedes	Total
Apr-11	21%	67%	47%	41%
May-11	45%	51%	43%	46%
Jun-11	29%	41%	19%	30%
Jul-11	35%	36%	-3%	24%
Aug-11	26%	9%	3%	14%
Sep-11	33%	21%	13%	24%
Oct-11	62%	34%	22%	41%
Nov-11	69%	11%	33%	38%
Dec-11	57%	9%	30%	33%
Jan-12	23%	31%	0%	19%

Source: Company data, Nomura research

## Current margins are largely in line with competitors

While we note that the 17% reported EBITDA margins (IFRS) in 4QCY11 appears abnormally high, we believe it is also because of the lower R&D expensing that happens in the P&L compared with that of other global OEMs. The adjusted EBIT margin (based on 60% expensing of R&D) was 10.6% in 4QCY11 compared with around 13% for Audi and 12% for BMW (both in 3Q CY11). Even Mercedes – which has a lower margin – plans to improve its margins by 200bps to 10% in 2012F.



**Fig. 8: EBIT margins for Luxury OEMS**

EBIT margins (%)	2QCY10	3QCY10	4QCY10	1QCY11	2QCY11	3QCY11	4QCY11
Audi	9.2	11.1	11.4	10.6	12.9	13.1	
BMW	9.6	8.1	10.2	11.9	14.4	11.9	
Mercedes	9.8	9.5	8.3	9.3	10.7	8.0	8.2
JLR (adj for R&D)	7.3	8.3	9.3	7.8	5.7	6.0	10.6

Source: Company, Nomura research

**Currency movements indicate a potential further 1% benefit for JLR margins in 4QFY12**

JLR is a net importer of raw materials from Europe and, therefore, it gains if the euro depreciates vis-a-vis the GBP. Similarly, due to exports, JLR also gains if the CNY and USD appreciate against GBP. As per the data below, the euro has further depreciated by 2.7% from 3QFY12 levels and CNY and USD have appreciated by 1.2% and 0.4%, respectively. This implies an additional positive impact of around 1% on JLR margins in 4QFY12, according to our calculations.

**Fig. 9: Currency movements and Impact on JLR's EBITDA margins**

	Currency movements vis-à-vis GBP					Net exposure					Change in OPM	
	EUR	RUB	CNY	USD	ROW	EUR	RUB	CNY	USD	ROW	Implied	Actual
Q4FY11	0.6%	-3.4%	0.4%	1.5%	1.5%	-19%	5%	12%	17%	17%	-0.3%	-1.3%
Q1FY12	-3.2%	-2.6%	0.5%	1.8%	1.8%	-20%	5%	15%	21%	19%	-1.3%	-1.0%
Q2FY12	0.6%	2.8%	-2.6%	-1.3%	-1.3%	-24%	6%	18%	19%	19%	0.9%	1.0%
Q3FY12	2.4%	4.5%	-3.3%	-2.4%	-2.4%	-16%	5%	17%	20%	17%	1.6%	2.6%
Q4FY12F	2.7%	-2.4%	-1.2%	-0.4%	-0.4%	-16%	5%	17%	20%	17%	0.9%	

Source: Company data, Bloomberg, Nomura research

**Standalone business continues to disappoint on weaker passenger vehicle business**

We believe that rate tightening and a slowdown in IIP will affect CV growth in FY13F. Therefore, we reduce our volume growth estimates to 5% for FY13F (from 8% earlier). Our total volume growth estimates are higher as we increase our volume growth estimates for the passenger vehicles segment (including Nano).

Overall, for the standalone business, we reduce our EPS estimates by 27% for FY12F and by 34% for FY13F. The reduction in our estimates is due to the cut in our EBITDA margins forecasts to 7.1% for FY12F (from 9.3%) and to 7.5% for FY13F (from 9.6%) owing to higher raw material cost and weaker-than-expected performance of the passenger vehicle segment. Note that we estimate a margin improvement of around 110bps in FY13F from the current levels (6.4% in 3QFY12) as we expect some reduction in losses in the passenger vehicle segment.

Fig. 10: Standalone estimates


	New			Old			% change		
	FY12F	FY13F	FY14F	FY12F	FY13F	FY14F	FY12F	FY13F	FY14F
<u>Standalone</u>									
MHCV volumes	226,284	237,598	256,606	226,284	244,386	262,869	-	(2.8)	(2.4)
% YoY	8.0%	5.0%	8.0%	8.0%	8.0%	7.6%			
LCV volumes	367,953	412,107	453,318	373,702	429,757	459,840	(1.5)	(4.1)	(1.4)
% YoY	28.0%	12.0%	10.0%	30.0%	15.0%	7.0%			
Car Volumes	192,842	202,484	218,683	154,274	161,987	174,946	25.0	25.0	25.0
% YoY	0.0%	5.0%	8.0%	-20.0%	5.0%	8.0%			
UV Volumes	47,369	52,106	56,275	43,063	47,369	51,159	10.0	10.0	10.0
% YoY	10.0%	10.0%	8.0%	0.0%	10.0%	8.0%			
Nano volumes	70,000	105,000	120,750	60,000	69,000	75,900	16.7	52.2	59.1
% YoY	-0.6%	50.0%	15.0%	-14.8%	15.0%	10.0%			
Total Volumes	974,448	1,114,295	1,226,381	917,322	1,021,500	1,100,614	6.2	9.1	11.4
% YoY	11.5%	14.4%	10.1%	5.0%	11.4%	7.7%			
Revenue (INR mn)	543,120	594,792	656,507	524,502	583,303	637,726	3.5	2.0	2.9
EBITDA (INR mn)	38,614	44,847	50,804	48,722	55,885	62,413	(20.7)	(19.8)	(18.6)
OPM(%)	7.1%	7.5%	7.7%	9.3%	9.6%	9.8%	(2.2)	(2.0)	(2.0)
EPS (INR)	4.7	5.0	6.0	6.4	7.7	8.8	(26.6)	(34.1)	(31.7)

Source: Nomura estimates

### Commercial vehicles segment remains strong

TTMT has been able to maintain its stronghold on the MHCV space. Its market share has been steady at around 60% despite increased competition from Mahindra and Eicher Motors. The company has regularly taken price increases in this segment to maintain margins. Also, it has been leading the space in terms of technology and new product introduction. While we expect FY13F to be a slow year for MHCVs, we believe that TTMT will be able to maintain market share.


Fig. 11: Market share (%) in domestic MHCVs



Source: SIAM, Nomura research

Within the LCV space TTMT has had to face increased competition from new products like Mahindra's Maxximo and Ashok Leyland's Dost. There has been some loss of market share in this segment, but the company maintained 28% volume growth in the first 10 months of FY12. TTMT plans to launch the World LCV and variants of the ACE family to sustain the volume momentum. We expect 12% volume growth for TTMT's LCV portfolio in FY13F.

**Fig. 12: Market share (%) in domestic LCVs**




Source: SIAM, Nomura research

**Not factoring in much improvement in the passenger vehicles segment**

We believe TTMT's domestic performance has been seriously hampered by the weak performance of the passenger vehicle division. The company is facing the brunt of increased competition in the mainstream car segments. In our view, given the competitive intensity, this business will require continuous supply of new products and thus high capex to sustain volume. TTMT launched a refreshed version of Tata Vista in August 2011 and a new model of Indigo in Sept-11. It also launched Sumo Gold in Nov-11 and Tata Nano (refresh) in Nov-11. The company is also looking to launch the diesel variant of Nano which could improve volume for the segment, in our view. However, the discount levels in passenger vehicles have increased significantly over FY11. We believe that the current situation is unsustainable and causing a big drag on domestic margins. Standalone margins are down from 9.7% in FY11F to 7% in 3QFY12. In our view, the entire decline in margins may be due to the PV division where the EBITDA losses may be close to INR8bn per annum.


We believe the current situation is unsustainable and the company may decide in the future to operate in fewer segments where it can be profitable. This could lead to an improvement in domestic margins as well as higher return on future capex, in our view. However, we have been conservative in not building in any significant improvement in our margin estimates over the next couple of years.

**Fig. 13: Market share (%) in domestic utility vehicles (UVs)**



Source: SIAM, Nomura research

**Fig. 14: Market share (%) in domestic cars segment**



Source: SIAM, Nomura research

**Consolidated earnings estimates increase by 50% for FY13F**

We increased our consolidated EPS estimates by 25% to INR34.3 for FY12F (INR27.4 earlier) and by 50% to INR44.0 for FY13F (from INR29.4) largely due to the increase in our estimates for the JLR business. We increase our JLR PAT estimates by 38% for FY12F and 68% for FY13F. JLR now accounts for ~85% of our consolidated estimates, according to our calculations. We note that GBP’s appreciation against INR has led to around a 6% increase in our consolidated EPS estimates.

Our FY13F consolidated EPS estimates are around 17% above consensus. Consensus is building in 17% margins for JLR, which is conservative, in our view. We expect consensus to upgrade earnings estimates if JLR reports strong margins in 4QFY12 and volume growth remains robust over the next few months.

Fig. 15: Our consolidated estimates are ahead of consensus

Standalone									
INR mn	Nomura			Consensus			% Difference		
	FY12F	FY13F	FY14F	FY12F	FY13F	FY14F	FY12F	FY13F	FY14F
Sales	543,120	594,792	656,507	530,823	598,765	680,182	2.3	-0.7	-3.5
EBITDA	38,614	44,847	50,804	40,290	48,601	58,374	-4.2	-7.7	-13.0
OPM	7.1%	7.5%	7.7%	7.6%	8.1%	8.6%	-0.5%	-0.6%	-0.8%
PAT	14,984	16,096	19,266	13,498	18,305	23,013	11.0	-12.1	-16.3
Consolidated									
INR mn	Nomura			Consensus			% Difference		
	FY12F	FY13F	FY14F	FY12F	FY13F	FY14F	FY12F	FY13F	FY14F
Sales	1,622,788	1,891,914	2,066,115	1,558,363	1,776,170	1,985,639	4.1	6.5	4.1
EBITDA	210,274	274,408	301,596	211,324	241,846	271,786	-0.5	13.5	11.0
OPM	13.0%	14.5%	14.6%	13.6%	13.6%	13.7%	-0.6%	0.9%	0.9%
PAT	109,507	140,417	152,654	108,775	120,383	131,181	0.7	16.6	16.4

Source: Bloomberg, Nomura estimates

## Maintain Buy with a new TP of INR326; offers 19% upside potential from current levels

We increased our TP for TTMT to INR326 from INR200 earlier. The increase is driven by four key reasons:

- 1) We increase our EBITDA estimates for the JLR business by ~60% for FY13-14F as we factor in our strong volume and margin expectations
- 2) We also increase our EV/EBITDA multiple for JLR to 3.0x (from 2.5x) to factor in the improvement in our valuations for other luxury OEMs and the stronger-than-expected performance of JLR. The higher JLR multiples have added around INR30 to our target price.
- 3) We roll forward our target price to Mar-13 from Mar-12 earlier. The roll-forward of the target price to FY14F earnings has added INR50 to our target price.
- 4) GBP appreciation against INR, which has added around INR10 to our target price.

Overall, our valuation for the JLR business has increased to INR219.3/share (from INR73.1). We reduce our standalone EBITDA estimates which has led to lower valuation for the standalone business.

Our 12-month forward TP of INR326 is calculated using the sum-of-the-parts methodology (methodology unchanged). We value the standalone business at INR80.0 on 8.0x FY14F EV/EBITDA and JLR at INR219.3 at 3.0x FY14F EV/EBITDA. We value other investments at INR26.8.

We note that based on our valuation, JLR is valued at 7.2x FY13F adjusted P/E compared with the sector average of 7.9x. Also, the FCF yield of JLR at 8.6% for FY13F is in line with the sector average of 9.1%.

Fig. 16: SOTP-based valuation of TTMT

New Valuation			New Valuation		
<i>Standalone Valuation</i>			<i>Standalone Valuation</i>		
	INR m			INR m	
Standalone EBITDA FY14F	50,804		Standalone EBITDA FY13E	55885	
Multiple	8.0		Multiple	8.0	
Standalone EV	406,429		Standalone EV	447082	
Standalone Net Debt	151,265		Standalone Net Debt	145279	
Standalone equity value	255,164		Standalone equity value	301803	
<b>Value / Share (INR)</b>	<b>80.0</b>		<b>Value / Share (INR)</b>	<b>94.7</b>	
<i>JLR Valuation</i>			<i>JLR Valuation</i>		
	( GBP m)			( GBP m)	
EBITDA (FY14)	241,044	3,013	EBITDA (FY13)	137971	1840
Normalized R&D expense (60% expensed)	34,608	433	Normalized R&D expense (60% expensed)	43981	586
Normalized EBITDA	206,437	2,580	Normalized EBITDA	93991	1253
Multiple (x)	3.0		Multiple (x)	2.5	
EV	619,311	7,741	EV	234977	3133
Debt	(79,906)	(999)	Debt	1748	23
Equity Value	699,217	8,740	Equity Value	233229	3110
<b>Value / Share (INR)</b>	<b>219.3</b>		<b>Value / Share (INR)</b>	<b>73.1</b>	
<b>Value of stake in Tata Sons and Tata Steel (INR/Sh)</b>	<b>7.1</b>		<b>Value of stake in Tata Sons and Tata Steel (INR/Sh)</b>	<b>6.2</b>	
<b>Value of Subsidiaries (INR/Share)</b>	<b>19.7</b>		<b>Value of Subsidiaries (INR/Share)</b>	<b>25.6</b>	
<b>Total Value</b>	<b>326.0</b>		<b>Total Value</b>	<b>200.0</b>	

Source: Nomura estimates

Fig. 17: Valuation of European OEMs

	Ticker	Rating	Price (LC)	EBITDA growth		EV/EBITDA			EV/sales			P/E			FCF Yield		
				FY13F	FY14F	FY12F	FY13F	FY14F	FY12F	FY13F	FY14F	FY12F	FY13F	FY14F	FY12F	FY13F	FY14F
BMW	BMW GR	NR	69.1	-5.0%	1.6%	2.5	2.6	2.5	0.52	0.47	0.42	9.0	9.3	8.9	8.9%	8.4%	7.3%
Daimler	DAI GR	NR	46.3	-1.6%	12.2%	2.8	2.8	2.5	0.34	0.30	0.27	8.9	7.8	7.2	7.6%	9.8%	14.9%
Volkswagen	VOW3 GY	NR	138.4	1.0%	10.9%	3.2	3.2	2.8	0.41	0.38	0.27	7.5	6.6	5.8	10.1%	9.2%	15.8%
<b>Average</b>				<b>-1.9%</b>	<b>8.2%</b>	<b>2.8</b>	<b>2.9</b>	<b>2.6</b>	<b>0.42</b>	<b>0.38</b>	<b>0.32</b>	<b>8.5</b>	<b>7.9</b>	<b>7.3</b>	<b>8.9%</b>	<b>9.1%</b>	<b>12.7%</b>
<b>JLR</b>	<b>Unlisted</b>	<b>NR</b>		<b>36.7%</b>	<b>11.3%</b>	<b>4.6</b>	<b>3.3</b>	<b>3.0</b>	<b>0.58</b>	<b>0.51</b>	<b>0.46</b>	<b>9.8</b>	<b>7.2</b>	<b>6.6</b>	<b>6.7%</b>	<b>8.6%</b>	<b>11.5%</b>

Note: Pricing as of 27 February 2012; JLR multiples are adjusted for R&amp;D expenditure

Source: Bloomberg consensus estimates for NR stocks

## Sensitivity analysis

Our target price for TTMT is highly sensitive for JLR margins and valuations multiples. The table below provides target price sensitivity to these variables.

Fig. 18: TP sensitivity to JLR multiple and margins

		JLR FY14F EV/EBITDA multiple			
		2.5	3.0	3.5	4.0
<b>JLR FY13F EBITDA margins (IFRS)</b>	<b>16%</b>	266	294	322	350
	<b>17%</b>	279	309	339	370
	<b>18%</b>	293	325	357	389
	<b>19%</b>	306	340	375	409

Source: Nomura research

## Key risks

### Downside risks

**JLR's volumes weakening:** JLR's margins are highly sensitive to volumes because of its high operating leverage. We assume JLR will be able to sustain strong volume growth. If volumes fall short of our assumptions, there could be a material downside risk to our estimates.

**Risks from a global growth slowdown:** Our base case scenario assumes slow and steady GDP growth in Europe and the US. If the economic growth in developed economies is weaker than expected or economies slip into a recession, there could be significant downside risks to our earnings estimates.

**Slower-than-expected growth in China:** Slower-than-expected growth in China volumes can lead to downside risks to our earnings estimates.

**Unfavorable currency movements:** JLR is a net importer of raw materials from Europe, and therefore, it gains if the euro depreciates vis-a-vis the GBP. Similarly, due to exports, JLR also gains if the CNY and USD appreciate against the GBP. If currencies move significantly in the opposite direction, there could be downside risks to our margin estimates.

## 3QFY12 results – Results above expectations on strong JLR performance

TTMT reported adj. consolidated PAT of INR35.7bn in 3QFY12 was significantly higher than our and consensus estimates. There was a forex loss of INR1.64bn during the quarter; our numbers are adjusted for the same.

The beat was due to better-than-expected performance of the JLR business driven by higher margins and realizations. As per IFRS, JLR's 3QFY12 EBITDA margins came in at 17%. However, as per the company, EBITDA (under IFRS) was lower by GBP60mn due to a one-off forex loss on revaluation of long-term monetary liabilities. Adjusted for this, margins were 18.6%, 340bps higher than our 15.2% estimate. As per the company, this is due to better product and geographical mix, as well as currency benefits.

### Key takeaways from conference call

#### JLR

- As per the company, the difference in EBITDA margins between IFRS (17%) and India GAAP (20.1%) was not due to any one-off losses related to AS-11 (Accounting Standard). The difference was due to: 1) product development expenses of GBP43mn are accounted for below EBITDA in Indian GAAP; and 2) IFRS EBITDA is after foreign exchange losses of around GBP60mn related to revaluation of long-term monetary liabilities, which is a one-off expense; however, in Indian GAAP, the one-off forex loss is accounted for below EBITDA.
- JLR's China sales volume increased 88% y-y in 3QFY12 and the company expects China to remain quite a growth driver for the company.
- As per the company, JLR will launch more than 30 new products/variants over the next 3-5 years. This should support volumes, in our view.
- Sales volume of the Freelander model declined 35% y-y in 3QFY12 as more production was diverted towards Evoque. There is no demand pressure, as per the company.

#### Standalone

- Margins during the quarter were impacted by higher marketing expenses. The company has taken a price increase on 1% on CVs and around 2% on PVs which should support margins going forward, in our view.
- As per management, although there is some demand pressure in some MHCV segments, the company continues to expect 8-10% growth ahead.
- Strong growth in LCVs is expected to continue and management expects improvement in the passenger vehicle segment due to the introduction of new model variants.

**Key result details****JLR: Strong results driven by higher-than-expected margins**

- JLR revenues came in at GBP3,749mn compared to our estimate of GBP3,539mn
- ASP came in at GBP43,430 per vehicle; 6% above our expectation of GBP41,000
- JLR adj EBITDA came in at GBP699mn (adj for one-off forex loss of GBP60mn) compared to our estimate of GBP 572mn
- Adjusted EBITDA margins at 18.6% were above our estimate of 15.2%
- Adjusted JLR PAT was GBP379mn compared to our estimate of GBP331mn.

**Standalone business: Margins disappoint on higher other expenses**

- Net sales at INR133.3bn were lower than our estimate of INR136.4bn
- EBITDA came in at INR8.5bn, much lower than our estimate of INR9.7bn
- EBITDA margins at 6.4% compared to our estimate of 7.1% due to higher other expenditure
- Adj PAT came in at INR2.56bn, compared to our estimate of INR3.0bn
- During the quarter, there was a one-off forex loss of INR0.83bn
- RM/Sales came in at 73.9% compared to our estimate of 74.0%
- Employee cost/sales came in at 5.2% compared to our estimate of 5.1%
- Other expenses/sales came in at 14.5% compared to our estimate of 13.8%

**Fig. 19: 3QFY12 consolidated results – Actual vs. estimates**

	INRmn			% difference from	
	Actual	Consensus	Nomura	Consensus	Nomura
Net Sales	452,603	419,558	449,099	7.9%	0.8%
Adj PAT	35,699	26,666	28,962	33.9%	23.3%

Source: Company data, Bloomberg, Nomura estimates



Fig. 20: Standalone 3QFY12 results review

INR mn	3QFY11A	2QFY12A	3QFY12A	Q/Q	Y/Y	3QFY12F
<b>Net Sales and Op. income</b>	<b>115,199</b>	<b>129,538</b>	<b>133,379</b>	<b>3.0%</b>	<b>15.8%</b>	<b>136,433</b>
(Inc)/Dec in Stocks	1,450	(319)	(4,351)			-
Raw Materials	79,220	96,080	102,951			-
Net Raw Materials	80,671	95,761	98,600	3.0%	22.2%	100,961
<b>RM/Sales</b>	<b>70.0%</b>	<b>73.9%</b>	<b>73.9%</b>	<b>0.0%</b>	<b>3.9%</b>	<b>74.0%</b>
Staff Welfare	5,809	6,829	6,950	1.8%	19.6%	6,958
Other Costs	17,033	18,219	19,311	6.0%	13.4%	18,828
Total Cost	103,513	120,809	124,861	3.4%	20.6%	126,747
<b>Operating Profit</b>	<b>11,686</b>	<b>8,729</b>	<b>8,518</b>	<b>-2.4%</b>	<b>-27.1%</b>	<b>9,687</b>
<b>OPM (%)</b>	<b>10.1</b>	<b>6.7</b>	<b>6.4</b>	<b>-35.3%</b>	<b>-375.8%</b>	<b>7.1</b>
Non-Operating Income	54	568	250			60
Extraordinary Income(+Forex)	-	(2,942)	(833)			-
Extraordinary Expense	305	-	-			-
Interest	2,749	2,121	1,860	-12.3%	-32.3%	2,121
Gross Profit	8,686	4,234	6,075	43.5%	-30.1%	7,625
Less: Depreciation	3,371	3,869	4,213	8.9%	25.0%	3,869
Amortisation	-	-	-			-
PBT	5,315	365	1,862	<b>410.2%</b>	<b>-65.0%</b>	3,756
Tax	1,211	(655)	125			751
Effective Tax Rate (%)	22.8	-179.5	6.7			20.0
<b>PAT</b>	<b>4,104</b>	<b>1,020</b>	<b>1,737</b>	<b>70.2%</b>	<b>-57.7%</b>	<b>3,005</b>
<b>Adj PAT</b>	<b>4,339</b>	<b>3,962</b>	<b>2,569</b>	<b>-35.2%</b>	<b>-40.8%</b>	<b>3,005</b>

Source: Company data, Nomura estimates

Fig. 21: Ratios – Standalone business

(%)	3QFY11A	2QFY12A	3QFY12A	Q/Q	Y/Y	3QFY12F
Staff cost / sales	5.0	5.3	5.2	-6.1%	-44.6%	5.1
Other expenses / sales	14.8	14.1	14.5	41.4%	2.2%	13.8
RM/ SALES	70.0	73.9	73.9	0.0%	-42.5%	74.0
Total	89.9	93.3	93.6	35.3%	-84.9%	92.9
OPM	10.1	6.7	6.4	-35.3%	-375.8%	7.1
Gross margins	30.0	26.1	26.1	0.0%	42.5%	26.00
Realisation per vehicle (INR)	616,793	620,578	583,282	-6.0%	-5.4%	600,735
Raw Material/ Vehicle (INR)	431,925	458,762	431,189	-6.0%	-0.2%	444,544
Operating Profit/Vehicle (INR)	62,567	41,819	37,248	-10.9%	-40.5%	42,652

Source: Company data, Nomura estimates

## Financials for Jaguar and Land Rover

Fig. 22: JLR – P&amp;L (GBP mn)

Year ended 31 Mar	FY11	FY12F	FY13F	FY14F
Total Volumes (Numbers)	243621	307565	357217	379994
YoY	25.6%	26.2%	16.1%	8.0%
Net Sales/vehicle (GBP)	40658	43191	42906	43815
	20.3%	6.2%	-0.7%	2.1%
(GBP mn)				
Total Revenue	9905	13284	15327	16650
YoY	51.1%	34.1%	15.4%	8.6%
RM cost	6195	8568	9809	10656
Product dev cost	122	146	154	161
Employee cost	800	968	1045	1150
Other exp	1291	1458	1560	1670
Total cost	8408	11141	12569	13637
EBITDA (excl product dev exp)	1620	2290	2912	3174
Margin	16.4%	17.2%	19.0%	19.1%
EBITDA *	1498	2143	2758	3013
EBITDA margin	15.1%	16.1%	18.0%	18.1%
Depreciation	380	480	637	742
interest	37	104	89	35
PBT	1099	1559	2032	2236
tax	82	327	488	581
PAT	1044	1232	1545	1655
cash earnings	1424	1712	2182	2397
Capex	-804	-1500	-1500	-1500
Excess/(Shortfall)	619	212	682	897

Note: \* As per IFRS

Source: Company data, Nomura estimates

Fig. 23: JLR – Balance Sheet (GBP mn)

Year ended 31 Mar	FY11	FY12F	FY13F	FY14F
Secured	824.3	824.3	824.3	824.3
Un Secured	436.7	568.4	67.1	(776.1)
Total Loans	1,261.0	1,392.7	891.4	48.1
<b>Total Funds</b>	2,941.3	4,304.8	5,348.1	6,159.6
Gross Fixed Assets	6,103.9	7,603.9	9,103.9	10,603.9
Acc. Depreciation	4,103.5	4,583.3	5,220.6	5,962.8
Net Fixed Assets	2,000.4	3,020.6	3,883.3	4,641.1
CWIP	1,030.3	1,030.3	1,030.3	1,030.3
<b>Fixed Assets</b>	3,030.6	4,050.8	4,913.6	5,671.3
<b>Goodwill</b>	375.8	375.8	375.8	375.8
<b>Investments</b>	105.3	105.3	105.3	105.3
Inventories	1,151.8	1,565.0	1,805.6	1,961.5
Sundry Debtors	561.7	753.3	881.8	957.9
Cash and Bank Balances	923.3	1,638.3	1,890.2	2,053.3
Loans & Advances	472.5	633.7	755.8	821.1
<b>Current Assets</b>	3,109.9	4,590.9	5,334.1	5,794.4
Current Liabilities	2,909.9	3,821.5	4,283.1	4,652.8
Provisions	825.1	1,051.2	1,152.2	1,189.1
<b>Total Current Liabilities</b>	3,735.0	4,872.7	5,435.3	5,841.8
<b>Net Current Assets</b>	(625.0)	(281.7)	(101.2)	(47.4)
<b>Deferred Tax Assets</b>	54.6	54.6	54.6	54.6
<b>Total Assets</b>	2,941.3	4,304.8	5,348.1	6,159.6

Source: Company data, Nomura estimates

Fig. 24: JLR – Cash Flow (GBP mn)

Year ended 31 Mar	FY11	FY12F	FY13F	FY14F
PAT	1,044	1,232	1,545	1,655
Depreciation	380	480	637	742
(Profit)/Loss on sale of Assets	-	-	-	-
Net Income Tax	82	327	488	581
Interest	37	104	89	35
Pension costs	-	-	-	-
Exchange Difference	-	-	-	-
	499	911	1,214	1,358
<b>Operating Profit</b>	<b>1,542</b>	<b>2,143</b>	<b>2,758</b>	<b>3,013</b>
(inc)/dec in WC	347	(343)	(181)	(54)
Tax refund (paid)	(82)	(327)	(488)	(581)
<b>Cash from operations</b>	<b>1,807</b>	<b>1,473</b>	<b>2,090</b>	<b>2,378</b>
	-	-	-	-
(Purchase) of Fixed Assets	(804)	(1,500)	(1,500)	(1,500)
Sale of Fixed Assets	-	-	-	-
Interest received	-	-	-	-
Purchase of JLR	-	-	-	-
<b>Net Cash from Investing</b>	<b>(804)</b>	<b>(1,500)</b>	<b>(1,500)</b>	<b>(1,500)</b>
	-	-	-	-
Issue of Pref shares	-	-	-	-
Increase in borrowings	(966)	132	(501)	(843)
Issue of ordinary shares	-	-	-	-
Dividend Paid	-	-	-	-
Interest paid	(37)	(104)	(89)	(35)
<b>Net cash used in Financing</b>	<b>(1,003)</b>	<b>27</b>	<b>(590)</b>	<b>(878)</b>

Source: Company data, Nomura estimates

## Standalone Financials

Fig. 25: Standalone – P&amp;L (INR mn)

Year ended 31 Mar (Rs mn)	FY10	FY11	FY12F	FY13F	FY14F
<b>Net sales</b>	<b>355,931</b>	<b>480,405</b>	<b>543,120</b>	<b>594,792</b>	<b>656,507</b>
grow th (%)	39.7	35.0	13.1	9.5	10.4
Operating expenses	(315,588)	(433,753)	(504,506)	(549,945)	(605,704)
<b>Operating profit (EBITDA)</b>	<b>40,343</b>	<b>46,652</b>	<b>38,614</b>	<b>44,847</b>	<b>50,804</b>
Depreciation	(10,339)	(13,608)	(15,656)	(17,497)	(19,171)
<b>EBIT</b>	<b>30,004</b>	<b>33,044</b>	<b>22,958</b>	<b>27,350</b>	<b>31,633</b>
Other income	18,535	1,833	2,088	2,186	2,290
Interest paid	(11,038)	(11,440)	(8,758)	(9,416)	(9,840)
<b>Pre-tax profit</b>	<b>37,500</b>	<b>23,437</b>	<b>16,287</b>	<b>20,120</b>	<b>24,083</b>
Extraordinary income(expense)	(9,205)	(1,471)	-	-	-
<b>PBT after extraordinary</b>	<b>28,295</b>	<b>21,965</b>	<b>16,287</b>	<b>20,120</b>	<b>24,083</b>
Tax (current + deferred)	(5,895)	(3,847)	(1,303)	(4,024)	(4,817)
<b>Profit after tax</b>	<b>22,401</b>	<b>18,118</b>	<b>14,984</b>	<b>16,096</b>	<b>19,266</b>
Adj. PAT	31,605	19,590	14,984	16,096	19,266
Adj. PAT ex subsidiary dividends	31,529	18,298	14,015	15,078	18,197
grow th (%)	2,782.1	(42.0)	(23.4)	7.6	20.7

Source: Company data, Nomura estimates

Fig. 26: Standalone – Balance Sheet (INR mn)

Year ended 31 Mar (Rs mn)	FY10	FY11	FY12F	FY13F	FY14F
Current assets	115,380	140,906	160,482	175,479	193,523
Investments	223,369	226,242	226,242	226,242	226,242
Net fixed assets	164,360	174,756	191,801	202,004	210,533
Other non-current assets	-	-	-	-	-
<b>Total assets</b>	<b>503,109</b>	<b>541,905</b>	<b>578,524</b>	<b>603,725</b>	<b>630,298</b>
Current liabilities	188,812	182,784	200,880	216,326	234,937
Total Debt	166,259	158,988	174,660	181,352	191,466
Other liabilities	(1,617)	-	-	-	-
<b>Total liabilities</b>	<b>353,455</b>	<b>341,772</b>	<b>375,540</b>	<b>397,677</b>	<b>426,403</b>
Share capital	5,706	6,377	6,377	6,377	6,377
Reserves & surplus	143,949	193,756	196,607	199,671	197,518
<b>Shareholders' funds</b>	<b>149,655</b>	<b>200,133</b>	<b>202,985</b>	<b>206,048</b>	<b>203,895</b>
Minorities	4,683	4,030	2,135	2,466	2,724
<b>Total equity &amp; liabilities</b>	<b>503,109</b>	<b>541,905</b>	<b>578,524</b>	<b>603,725</b>	<b>630,298</b>

Source: Company data, Nomura estimates

Fig. 27: Standalone – Cash Flow (INR mn)

Year ended 31 Mar (Rs mn)	FY10	FY11	FY12F	FY13F	FY14F
PAT	22,401	18,118	14,984	16,096	19,266
less: Proposed dividend	9,919	14,670	12,133	13,033	15,600
Depreciation	10,339	13,608	15,656	17,497	19,171
<b>Operating cashflow</b>	<b>22,820</b>	<b>17,056</b>	<b>18,507</b>	<b>20,560</b>	<b>22,837</b>
Change in WC	(53,336)	31,555	1,480	(448)	(568)
Change in fixed assets (Capex)	27,898	22,929	32,700	27,700	27,700
Change in Intangibles	(20)	-	-	-	-
<b>Free cash flow</b>	<b>48,279</b>	<b>(37,428)</b>	<b>(15,673)</b>	<b>(6,692)</b>	<b>(4,295)</b>
<b>Financing Cashflow</b>					
Increase in debt	31,360	(6,731)	15,673	6,692	10,114
Less: Increase in Investments	93,688	2,873	-	-	-
Increase in share capital	566	671	-	-	-
Increase in share premium	13,483	46,361	-	-	(5,819)
Others	-	-	-	-	-
<b>Financing Cashflow</b>	<b>(48,279)</b>	<b>37,428</b>	<b>15,673</b>	<b>6,692</b>	<b>4,295</b>

Source: Company data, Nomura estimates

# Appendix A-1

## Analyst Certification

We, Kapil Singh and Nishit Jalan, hereby certify (1) that the views expressed in this Research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this Research report, (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this Research report and (3) no part of our compensation is tied to any specific investment banking transactions performed by Nomura Securities International, Inc., Nomura International plc or any other Nomura Group company.

## Issuer Specific Regulatory Disclosures

The term "Nomura Group Company" used herein refers to Nomura Holdings, Inc. or any affiliate or subsidiary of Nomura Holdings, Inc. Nomura Group Companies involved in the production of Research are detailed in the disclaimer below.

Issuer name	Ticker	Price	Price date	Stock rating	Sector rating	Disclosures
Tata Motors	TTMT IN	INR 273	28-2-2012	Buy	Not rated	A6

A6 A Nomura Group Company expects to receive or intends to seek compensation for investment banking services from the issuer in the next three months.


## Previous Rating

Issuer name	Previous Rating	Date of change
Tata Motors	Neutral	21-9-2011

### Tata Motors (TTMT IN)

INR 273 (28-2-2012) Buy (Sector rating: Not rated)

Rating and target price chart (three year history)



For explanation of ratings refer to the stock rating keys located after chart(s)

**Valuation Methodology** Our 12-month forward TP of INR326 is calculated using the sum-of-the-parts methodology. We value the standalone business at INR80.0 on 8.0x FY14F EV/EBITDA and JLR at INR219.3 at 3.0x FY14F EV/EBITDA. We value other investments at INR26.8.

**Risks that may impede the achievement of the target price** Downside risks JLR's volumes weakening: JLR's margins are highly sensitive to volumes because of its high operating leverage. We assume JLR will be able to sustain the strong volume growth. If volumes fall short of our assumptions, there could be a material downside risk to our estimates. Risks from a global growth slowdown: Our base case scenario assumes a slow and steady GDP growth in Europe and the US. If the economic growth in developed economies is weaker than expected or economies slip into a recession, there could be significant downside risks to our earnings estimates. Slower than expected growth in China: Slower than expected growth in China volumes can lead to downside risks to our earnings estimates. Unfavorable currency movements: JLR is a net importer of raw materials from Europe and therefore, it gains if Euro depreciates vis-a-vis GBP. Similarly, due to exports, JLR also gains if CNY and USD

appreciates against GBP. If currencies move significantly in the opposite direction, there could be downside risks to our margin estimates.

## Important Disclosures

### Online availability of research and conflict-of-interest disclosures

Nomura research is available on [www.nomuranow.com](http://www.nomuranow.com), Bloomberg, Capital IQ, Factset, MarkitHub, Reuters and ThomsonOne.

Important disclosures may be read at <http://go.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.aspx> or requested from Nomura Securities International, Inc., on 1-877-865-5752. If you have any difficulties with the website, please email [grpsupport-eu@nomura.com](mailto:grpsupport-eu@nomura.com) for help.

The analysts responsible for preparing this report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by Investment Banking activities. Unless otherwise noted, the non-US analysts listed at the front of this report are not registered/qualified as research analysts under FINRA/NYSE rules, may not be associated persons of NSI, and may not be subject to FINRA Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

Any authors named in this report are research analysts unless otherwise indicated. *Industry Specialists* identified in some Nomura International plc research reports are employees within the Firm who are responsible for the sales and trading effort in the sector for which they have coverage. Industry Specialists do not contribute in any manner to the content of research reports in which their names appear. *Marketing Analysts* identified in some Nomura research reports are research analysts employed by Nomura International plc who are primarily responsible for marketing Nomura's Equity Research product in the sector for which they have coverage. Marketing Analysts may also contribute to research reports in which their names appear and publish research on their sector.

### Distribution of ratings (US)

The distribution of all ratings published by Nomura US Equity Research is as follows:

35% have been assigned a Buy rating which, for purposes of mandatory disclosures, are classified as a Buy rating; 11% of companies with this rating are investment banking clients of the Nomura Group\*.

59% have been assigned a Neutral rating which, for purposes of mandatory disclosures, is classified as a Hold rating; 2% of companies with this rating are investment banking clients of the Nomura Group\*.

6% have been assigned a Reduce rating which, for purposes of mandatory disclosures, are classified as a Sell rating; 0% of companies with this rating are investment banking clients of the Nomura Group\*.

As at 31 December 2011. \*The Nomura Group as defined in the Disclaimer section at the end of this report.

### Distribution of ratings (Global)

The distribution of all ratings published by Nomura Global Equity Research is as follows:

47% have been assigned a Buy rating which, for purposes of mandatory disclosures, are classified as a Buy rating; 40% of companies with this rating are investment banking clients of the Nomura Group\*.

43% have been assigned a Neutral rating which, for purposes of mandatory disclosures, is classified as a Hold rating; 45% of companies with this rating are investment banking clients of the Nomura Group\*.

10% have been assigned a Reduce rating which, for purposes of mandatory disclosures, are classified as a Sell rating; 21% of companies with this rating are investment banking clients of the Nomura Group\*.

As at 31 December 2011. \*The Nomura Group as defined in the Disclaimer section at the end of this report.

### Explanation of Nomura's equity research rating system in Europe, Middle East and Africa, US and Latin America

The rating system is a relative system indicating expected performance against a specific benchmark identified for each individual stock.

Analysts may also indicate absolute upside to target price defined as (fair value - current price)/current price, subject to limited management discretion. In most cases, the fair value will equal the analyst's assessment of the current intrinsic fair value of the stock using an appropriate valuation methodology such as discounted cash flow or multiple analysis, etc.

### STOCKS

A rating of '**Buy**', indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of '**Neutral**', indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of '**Reduce**', indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of '**Suspended**', indicates that the rating, target price and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including, but not limited to, when Nomura is acting in an advisory capacity in a merger or strategic transaction involving the company.

Benchmarks are as follows: **United States/Europe**: Please see valuation methodologies for explanations of relevant benchmarks for stocks (accessible through the left hand side of the Nomura Disclosure web page: <http://go.nomuranow.com/research/globalresearchportal>); **Global Emerging Markets (ex-Asia)**: MSCI Emerging Markets ex-Asia, unless otherwise stated in the valuation methodology.

### SECTORS

A '**Bullish**' stance, indicates that the analyst expects the sector to outperform the Benchmark during the next 12 months. A '**Neutral**' stance, indicates that the analyst expects the sector to perform in line with the Benchmark during the next 12 months. A '**Bearish**' stance, indicates that the analyst expects the sector to underperform the Benchmark during the next 12 months.

Benchmarks are as follows: **United States**: S&P 500; **Europe**: Dow Jones STOXX 600; **Global Emerging Markets (ex-Asia)**: MSCI Emerging Markets ex-Asia.

### Explanation of Nomura's equity research rating system in Japan and Asia ex-Japan

#### STOCKS

Stock recommendations are based on absolute valuation upside (downside), which is defined as (Target Price - Current Price) / Current Price, subject to limited management discretion. In most cases, the Target Price will equal the analyst's 12-month intrinsic valuation of the stock, based on an appropriate valuation methodology such as discounted cash flow, multiple analysis, etc.

A '**Buy**' recommendation indicates that potential upside is 15% or more. A '**Neutral**' recommendation indicates that potential upside is less than 15% or downside is less than 5%. A '**Reduce**' recommendation indicates that potential downside is 5% or more. A rating of '**Suspended**' indicates that the rating and target price have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including when Nomura is acting in an advisory capacity in a merger or strategic transaction involving the subject company.



Securities and/or companies that are labelled as '**Not rated**' or shown as '**No rating**' are not in regular research coverage of the Nomura entity identified in the top banner. Investors should not expect continuing or additional information from Nomura relating to such securities and/or companies.

#### **SECTORS**

A '**Bullish**' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a positive absolute recommendation. A '**Neutral**' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a neutral absolute recommendation. A '**Bearish**' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a negative absolute recommendation.

#### **Target Price**

A Target Price, if discussed, reflect in part the analyst's estimates for the company's earnings. The achievement of any target price may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market, and may not occur if the company's earnings differ from estimates.

## Disclaimers

This document contains material that has been prepared by the Nomura entity identified at the top or bottom of page 1 herein, if any, and/or, with the sole or joint contributions of one or more Nomura entities whose employees and their respective affiliations are specified on page 1 herein or identified elsewhere in the document. Affiliates and subsidiaries of Nomura Holdings, Inc. (collectively, the 'Nomura Group'), include: Nomura Securities Co., Ltd. ('NSC') Tokyo, Japan; Nomura International plc ('Nlplc'), UK; Nomura Securities International, Inc. ('NSI'), New York, US; Nomura International (Hong Kong) Ltd. ('NIHK'), Hong Kong; Nomura Financial Investment (Korea) Co., Ltd. ('NFIK'), Korea (Information on Nomura analysts registered with the Korea Financial Investment Association ('KOFIA') can be found on the KOFIA Intranet at <http://dis.kofia.or.kr>); Nomura Singapore Ltd. ('NSL'), Singapore (Registration number 197201440E, regulated by the Monetary Authority of Singapore); Capital Nomura Securities Public Company Limited ('CNS'), Thailand; Nomura Australia Ltd. ('NAL'), Australia (ABN 48 003 032 513), regulated by the Australian Securities and Investment Commission ('ASIC') and holder of an Australian financial services licence number 246412; P.T. Nomura Indonesia ('PTNI'), Indonesia; Nomura Securities Malaysia Sdn. Bhd. ('NSM'), Malaysia; Nomura International (Hong Kong) Ltd., Taipei Branch ('NITB'), Taiwan; Nomura Financial Advisory and Securities (India) Private Limited ('NFASL'), Mumbai, India (Registered Address: Ceejay House, Level 11, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai- 400 018, India; Tel: +91 22 4037 4037, Fax: +91 22 4037 4111; SEBI Registration No: BSE INB011299030, NSE INB231299034, INF231299034, INE 231299034, MCX: INE261299034); Banque Nomura France ('BNF'), regulated by the Autorité des marchés financiers and the Autorité de Contrôle Prudentiel; Nlplc, Dubai Branch ('Nlplc, Dubai'); Nlplc, Madrid Branch ('Nlplc, Madrid') and Nlplc, Italian Branch ('Nlplc, Italy').

This material is: (i) for your private information, and we are not soliciting any action based upon it; (ii) not to be construed as an offer to sell or a solicitation of an offer to buy any security in any jurisdiction where such offer or solicitation would be illegal; and (iii) based upon information from sources that we consider reliable, but has not been independently verified by Nomura Group.

Nomura Group does not warrant or represent that the document is accurate, complete, reliable, fit for any particular purpose or merchantable and does not accept liability for any act (or decision not to act) resulting from use of this document and related data. To the maximum extent permissible all warranties and other assurances by Nomura group are hereby excluded and Nomura Group shall have no liability for the use, misuse, or distribution of this information.

Opinions or estimates expressed are current opinions as of the original publication date appearing on this material and the information, including the opinions and estimates contained herein, are subject to change without notice. Nomura Group is under no duty to update this document. Any comments or statements made herein are those of the author(s) and may differ from views held by other parties within Nomura Group. Clients should consider whether any advice or recommendation in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. Nomura Group does not provide tax advice.

Nomura Group, and/or its officers, directors and employees, may, to the extent permitted by applicable law and/or regulation, deal as principal, agent, or otherwise, or have long or short positions in, or buy or sell, the securities, commodities or instruments, or options or other derivative instruments based thereon, of issuers or securities mentioned herein. Nomura Group companies may also act as market maker or liquidity provider (as defined within Financial Services Authority ('FSA') rules in the UK) in the financial instruments of the issuer. Where the activity of market maker is carried out in accordance with the definition given to it by specific laws and regulations of the US or other jurisdictions, this will be separately disclosed within the specific issuer disclosures.

This document may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information, including ratings, and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice.

Any MSCI sourced information in this document is the exclusive property of MSCI Inc. ('MSCI'). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, re-disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI and the MSCI indexes are services marks of MSCI and its affiliates. Investors should consider this document as only a single factor in making their investment decision and, as such, the report should not be viewed as identifying or suggesting all risks, direct or indirect, that may be associated with any investment decision. Nomura Group produces a number of different types of research product including, among others, fundamental analysis, quantitative analysis and short term trading ideas; recommendations contained in one type of research product may differ from recommendations contained in other types of research product, whether as a result of differing time horizons, methodologies or otherwise. Nomura Group publishes research product in a number of different ways including the posting of product on Nomura Group portals and/or distribution directly to clients. Different groups of clients may receive different products and services from the research department depending on their individual requirements.

Figures presented herein may refer to past performance or simulations based on past performance which are not reliable indicators of future performance. Where the information contains an indication of future performance, such forecasts may not be a reliable indicator of future performance. Moreover, simulations are based on models and simplifying assumptions which may oversimplify and not reflect the future distribution of returns.

Certain securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment. The securities described herein may not have been registered under the US Securities Act of 1933 (the '1933 Act'), and, in such case, may not be offered or sold in the US or to US persons unless they have been registered under the 1933 Act, or except in compliance with an exemption from the registration requirements of the 1933 Act. Unless governing law permits otherwise, any transaction should be executed via a Nomura entity in your home jurisdiction.

This document has been approved for distribution in the UK and European Economic Area as investment research by Nlplc, which is authorized and regulated by the FSA and is a member of the London Stock Exchange. It does not constitute a personal recommendation, as defined by the FSA, or take into account the particular investment objectives, financial situations, or needs of individual investors. It is intended only for investors who are 'eligible counterparties' or 'professional clients' as defined by the FSA, and may not, therefore, be redistributed to retail clients as defined by the FSA. This document has been approved by NIHK, which is regulated by the Hong Kong Securities and Futures Commission, for distribution in Hong Kong by NIHK. This document has been approved for distribution in Australia by NAL, which is authorized and regulated in Australia by the ASIC. This document has also been approved for distribution in Malaysia by NSM. In Singapore, this document has been distributed by NSL. NSL accepts legal responsibility for the content of this document, where it concerns securities, futures and foreign exchange, issued by their foreign affiliates in respect of recipients who are not accredited, expert or institutional investors as defined by the Securities and Futures Act (Chapter 289). Recipients of this document in Singapore should contact NSL in respect of matters arising from, or in connection with, this document. Unless prohibited by the provisions of Regulation S of the 1933 Act, this material is distributed in the US, by NSI, a US-registered broker-dealer, which accepts responsibility for its contents in accordance with the provisions of Rule 15a-6, under the US Securities Exchange Act of 1934.

This document has not been approved for distribution in the Kingdom of Saudi Arabia ('Saudi Arabia') or to clients other than 'professional clients' in the United Arab Emirates ('UAE') by Nomura Saudi Arabia, Nlplc or any other member of Nomura Group, as the case may be. Neither this document nor any copy thereof may be taken or transmitted or distributed, directly or indirectly, by any person other than those authorised to do so into Saudi Arabia or in the UAE or to any person located in Saudi Arabia or to clients other than 'professional clients' in the UAE. By accepting to receive this document, you represent that you are not located in Saudi Arabia or that you are a 'professional client' in the UAE and agree to comply with these restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of Saudi Arabia or the UAE.

NO PART OF THIS MATERIAL MAY BE (I) COPIED, PHOTOCOPIED, OR DUPLICATED IN ANY FORM, BY ANY MEANS; OR (II) REDISTRIBUTED WITHOUT THE PRIOR WRITTEN CONSENT OF A MEMBER OF NOMURA GROUP. If this document has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this document, which may arise as a result of electronic transmission. If verification is required, please request a hard-copy version.

Nomura Group manages conflicts with respect to the production of research through its compliance policies and procedures (including, but not limited to, Conflicts of Interest, Chinese Wall and Confidentiality policies) as well as through the maintenance of Chinese walls and employee training.

**Additional information is available upon request and disclosure information is available at the Nomura Disclosure web page:** <http://go.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.aspx>